HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

Approval of Novel Antiepileptic Drugs as Monotherapies Coming Closer to Reality

Lexicon

Japan Medical Association (JMA):
日本医師会

The Column

Emerging Immunotherapy of Cancer: 2

Archives

DPJ Member Nagatsuma Asks MHLW to Consider Criminal Complaint over SIGN Trial (Apr.18)
New Health Ministry Panel to Compile Report on Clinical Research Regulations by Autumn (Apr.18)
Astellas Launches Japan’s 1st SGLT-2 Inhibitor Suglat (Apr.18)
Blue Letter on Xeplion Issued Following 21 Reported Deaths; Causal Relationship Remains Unclear (Apr.18)
Dainippon’s Takada to Head JPMA Public Affairs Committee (Apr.18)

Most Read

1.
Rattled Confide...
2.
MHLW Diovan Pan...
3.
Japan NIH Will ...
4.
Pharma Leaders ...
5.
10% of Valsarta...

News Calendar